Trexquant Investment’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-66,656
| Closed | -$3.61M | – | 1599 |
|
|
2025
Q3 | $3.61M | Buy |
+66,656
| New | +$3.81M | 0.04% | 677 |
|
|
2025
Q2 | – | Sell |
-207,172
| Closed | -$14.6M | – | 1533 |
|
|
2025
Q1 | $14.6M | Sell |
207,172
-11,868
| -5% | -$798K | 0.17% | 148 |
|
|
2024
Q4 | $14.4M | Sell |
219,040
-91,662
| -30% | -$6.14M | 0.17% | 169 |
|
|
2024
Q3 | $21.8M | Buy |
310,702
+180,201
| +138% | +$15.1M | 0.28% | 68 |
|
|
2024
Q2 | $10.7M | Buy |
130,501
+113,896
| +686% | +$9.48M | 0.16% | 166 |
|
|
2024
Q1 | $1.45M | Buy |
+16,605
| New | +$1.49M | 0.03% | 774 |
|
|
2023
Q4 | – | Sell |
-61,605
| Closed | -$5.45M | – | 1441 |
|
|
2023
Q3 | $5.45M | Sell |
61,605
-60,175
| -49% | -$5.35M | 0.14% | 208 |
|
|
2023
Q2 | $10.6M | Buy |
+121,780
| New | +$11.5M | 0.28% | 76 |
|
|
2022
Q3 | – | Sell |
-3,555
| Closed | -$295K | – | 1377 |
|
|
2022
Q2 | $295K | Sell |
3,555
-36,379
| -91% | -$2.9M | 0.01% | 1128 |
|
|
2022
Q1 | $3.08M | Buy |
+39,934
| New | +$3.34M | 0.14% | 176 |
|
|
2021
Q4 | – | Sell |
-35,967
| Closed | -$2.78M | – | 1311 |
|
|
2021
Q3 | $2.78M | Buy |
35,967
+25,943
| +259% | +$2.05M | 0.22% | 118 |
|
|
2021
Q2 | $836K | Sell |
10,024
-3,694
| -27% | -$293K | 0.07% | 348 |
|
|
2021
Q1 | $1.04M | Buy |
+13,718
| New | +$1.12M | 0.1% | 269 |
|
|
2020
Q4 | – | Sell |
-8,854
| Closed | -$674K | – | 1040 |
|
|
2020
Q3 | $674K | Sell |
8,854
-11,643
| -57% | -$1.18M | 0.04% | 556 |
|
|
2020
Q2 | $2.53M | Buy |
20,497
+3,102
| +18% | +$308K | 0.18% | 158 |
|
|
2020
Q1 | $1.47M | Buy |
+17,395
| New | +$1.5M | 0.11% | 290 |
|
|
2019
Q3 | – | Sell |
-22,049
| Closed | -$1.89M | – | 870 |
|
|
2019
Q2 | $1.89M | Buy |
+22,049
| New | +$1.89M | 0.17% | 174 |
|
|
2018
Q2 | – | Sell |
-13,397
| Closed | -$1.09M | – | 912 |
|
|
2018
Q1 | $1.09M | Buy |
+13,397
| New | +$1.15M | 0.08% | 388 |
|
|
2016
Q3 | – | Sell |
-3,700
| Closed | -$288K | – | 739 |
|
|
2016
Q2 | $288K | Buy |
+3,700
| New | +$315K | 0.04% | 677 |
|
|
2015
Q4 | – | Sell |
-27,900
| Closed | -$2.94M | – | 1015 |
|
|
2015
Q3 | $2.94M | Buy |
27,900
+22,500
| +417% | +$3.01M | 0.25% | 68 |
|
|
2015
Q2 | $738K | Sell |
5,400
-14,682
| -73% | -$1.82M | 0.08% | 457 |
|
|
2015
Q1 | $2.5M | Buy |
+20,082
| New | +$2.13M | 0.26% | 54 |
|
Other funds holding BMRN
Trexquant Investment's BMRN Position: Q4 2025 in Review
Trexquant Investment sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 66,656 shares — an estimated $3.61M sold.
Trexquant Investment first reported a position in BMRN in Q1 2015 and held it in 22 quarters. The position peaked at $21.8M in Q3 2024. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Trexquant Investment reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Trexquant Investment sold 66,656 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $3.61M.
- Trexquant Investment first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 22 quarters.
- Trexquant Investment's BioMarin Pharmaceuticals position peaked at $21.8M in Q3 2024.
- 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Trexquant Investment's 13F filing for Q4 2025, filed 17 Feb 2026.